– USA, NY – Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company today announced the appointments of Dr. Ellen Strahlman and Dr. Ram Palanki to its Board as Independent Directors, expanding the Board to eight members.
“I could not be more pleased to welcome Drs. Strahlman and Palanki to our Board and look forward to their immediate contributions. Each brings decades of medical technology, clinical development, launch, and commercialization experience, much of it specific to ophthalmology. This cross-functional expertise rounds out what I believe to be a world-class Board, especially at a time when we have significant clinical and regulatory milestones rapidly approaching,” said CEO and CMO, Dr. Sean Ianchulev.
Dr. Strahlman will join the compensation and audit committees, while Dr. Palanki will serve on the compensation committee.
About Dr. Ellen R. Strahlman
Dr. Ellen Strahlman brings to the Board C-suite executive experience at multiple global healthcare companies. She is passionate about innovation that transforms and democratizes technology into products that help people, with an accompanying track record of delivering value to the business through her philosophy of servant leadership.
Dr. Strahlman served as EVP, Research & Development, and CMO of Becton, Dickinson, and Company (NYSE: BDX), a leading global medical technology company, from 2013 until her retirement in 2018. While at BD, the company was selected as the Outstanding Corporate Innovator in 2015 by the Product Development & Management Association. Before joining BD, she served as SVP and CMO for GlaxoSmithKline, plc from 2008 to 2013, spending her last year at GSK as Senior Advisor to the CEO, leading GSK’s Global Health Programs. Before 2008, Dr. Strahlman held senior executive leadership roles in global product development and commercialization and business development at Pfizer, Inc., Novartis AG, Virgen Limited, and Merck & Co., Inc. She was SVP for Research & Development and CMO for Bausch & Lomb from 1995 to 2000.
Dr. Strahlman was chosen to serve as Industry Representative on the FDA/CDER Dermatology and Ophthalmology Advisory Committee, from 2008 to 2013. From 2016 to November 2020, Dr. Strahlman served as a director of Syncona Limited (LSE: SYNC.L), having previously served as a director of Syncona Partners, LLP. She is currently a director of Altria Group, Inc. (NYSE: MO). In addition to her corporate board service, Dr. Strahlman serves as a visiting professor at the University of Turku in Finland.
Dr. Strahlman earned a BA from Harvard University in biochemistry and an MD from the Johns Hopkins School of Medicine. She is an American Board of Ophthalmology board-certified ophthalmologist, having trained at the Wilmer Eye Institute from 1984 to 1987. She was awarded a Carnegie Mellon Public Health Fellowship in 1987, during which she earned an MHSc in Epidemiology from the Bloomberg School of Public Health (1987-1989).
Dr. Ram Palanki
Dr. Ram Palanki currently serves as EVP of Commercial Strategy & Operations at REGENXBIO (Nasdaq: RGNX), a leader in AAV gene therapy, and is responsible for the planning, execution, and commercialization of their pipeline across the ophthalmology, central nervous system, and neuromuscular disease franchises.
Dr. Palanki has nearly 20 years of experience in the development and commercialization of biopharmaceuticals and medical devices. Before joining REGENXBIO, Dr. Palanki was SVP of Commercial for the Americas at Santen Inc. Previously, he served as the executive team member leading the strategy and operations for the pre-launch and global commercialization of a first-in-class biologic at ThromboGenics (now known as Oxurion, Euronext Brussels: OXUR). Throughout his career, Dr. Palanki has held roles of increasing responsibility at several small, mid-sized and large companies, including the launch of LUCENTIS at Genentech. He is an active board member and strategic advisor to multiple biotech companies, technology start-ups, and global non-profits.
Ram holds a PharmD from Albany College of Pharmacy, Union University, NY, and his post-doctorate from Rutgers University, NJ.
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression.
For more information: https://eyenovia.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.